Application Notes & Whitepapers 2017
16 January 2018 | By European Pharmaceutical Review
This supplement contains a collection of application notes and whitepapers from some of the leading suppliers to the pharmaceutical industry...
List view / Grid view
16 January 2018 | By European Pharmaceutical Review
This supplement contains a collection of application notes and whitepapers from some of the leading suppliers to the pharmaceutical industry...
6 February 2017 | By Niamh Marriott (European Pharmaceutical Review)
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
29 October 2010 | By Klara Valko, Analytical Chemistry, GlaxoSmithKline Medicines Research Centre
A major concern for the pharmaceutical industry is the high attrition rate (>90 per cent) of potential drug molecules failing during late stages of the drug discovery process. This may be due to lack of efficacy in the clinic, unexpected side effects or unfavourable pharmacokinetics. There is a need for…
3 September 2019 | By Christian Rack (Qualified Person - B. Braun Gruppe)
The efficient handling of information and resources is key for achieving success within a commercial organisation. Against the backdrop of ICH Q10 – the International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use – Christian Rack discusses five things you can implement right now to…
14 October 2019 | By Victoria Rees (European Pharmaceutical Review)
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
18 April 2017 | By Mahfoozur Rahman (Sam Higginbottom Institute of Agriculture), Sagar Suman Panda (Roland Institute of Pharmaceutical Sciences), Sawar Beg (Jubilant Generics Limited)
The concept of Quality by Design (QbD) was implemented by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and United States Food and Drug Administration (FDA) around a decade ago, with the aim of adopting systematic approaches for developing high-quality pharmaceutical products for patients’…
17 February 2021 | By Bastiaan Dickhoff (DFE Pharma), Sunil Kumar Nataraj (DFE Pharma), Thontesh GC (Apotex Pharmaceuticals)
Many biologic formulations use a variety of high-purity injectable grade disaccharide excipients to ensure functionality and stability of the final product. In this article, Sunil Kumar Nataraj, Bastiaan Dickhoff and Thontesh GC explore the use of these sugars in the stabilisation of biologics and provide recommendations to manufacturers for enhancing…
28 August 2020 | By Andrew Dunbar (Appnovation)
Andrew Dunbar outlines five digital technologies that can help pharma function to the best of its abilities over the course of the COVID-19 pandemic.
23 October 2018 | By David Lovett (Perceptive Engineering Ltd), Dennis Powers - Vice President of Business Development & Sales Engineering G-CON Manufacturing Inc., Jan Verelst - Global Business Development Manager for SIPAT at Siemens, Marco Bellentani Product Manager for Containment and Innovative Solutions at MG2, Massimo Bresciani - R&D Executive Director for Business Development & Scientific Operation at RCPE, Richard Steiner - Business Development Manager for continuous oral solid dosage (OSD) systems at GEA
Welcome to European Pharmaceutical Review’s roundtable devoted to continuous manufacturing. We have brought together six industry experts to focus on how the contribution of continuous manufacturing technology is shaping the pharmaceutical sector and explain what factors are driving that change.
16 February 2011 | By Isabel Coma & Julio J. Martin, Screening and Compound Profiling, GlaxoSmithKline R&D Pharmaceuticals
Cell signalling circuits are likely to have a key role in the future of pharmacological discovery and medical treatment. There is consensus about the importance of understanding cell components and their function, not at the level of genes, but at a higher level of abstraction, involving their pathways and circuits.…
17 September 2015 | By Radwag
Advanced Radwag solutions for traceability of measurement...
26 August 2021 | By Ceri Roberts (NHS Blood and Transplant), Rachel Bell (Marks & Clerk)
Advanced therapies are a ground-breaking new class of medicines that use gene therapy, cell therapy or tissue engineering to treat disease and injury. Rachel Bell, Trainee Patent Attorney at Marks & Clerk, and Ceri Roberts, Scientific Training Manager – Cellular and Molecular Therapies at NHS Blood and Transplant, discuss some…
2 August 2008 | By
Differential scanning calorimetry (DSC) is a widely used technique within the pharmaceutical industry because the range of phase transitions it can measure usually allows near complete physical characterisation of a new active principal early during preformulation. In addition, because DSC measures a property change that is ubiquitous† (heat) there are…
14 June 2022 | By Karen Winterhalter (Onyx Health)
The pandemic has been a game-changer for the pharmaceutical industry, sending the seemingly inexorable globalisation trends into reverse, with Big Pharma increasingly seeking more domestic supply chain options. Here, Karen Winterhalter of Onyx Health shares her expert insights on the impact of this emerging trend on the industry.
19 August 2010 | By Karol Kozak, Angela Bauch, Gabor Csucs,Tomasz Pylak & Bernd Rinn, ETH Zurich
As High Content Screening (HCS) has moved into the mainstream for biological and pharmaceutical investigations, a lag of well integrated pipelines for automated acquisition, management and analysis of HCS results turns out to be a bottleneck for fully leveraging the wealth of information contained in a screen and moving to…